MAPT and Alzheimer disease: In agreement, Schmidt and colleagues found significantly elevated levels of NSE in the CSF of AD patients compared to the control group, confirming its role as a biomarker of cognitive impairment and its direct correlation with T-Tau and P-Tau [51].